103 related articles for article (PubMed ID: 32036219)
1. Elevated SRC3 expression predicts pemetrexed resistance in lung adenocarcinoma.
Chen Y; Sun Y; Zhao W; Ma Y; Yan Z; Nie X
Biomed Pharmacother; 2020 May; 125():109958. PubMed ID: 32036219
[TBL] [Abstract][Full Text] [Related]
2. Identification of Up- and Down-Regulated Proteins in Pemetrexed-Resistant Human Lung Adenocarcinoma: Flavin Reductase and Calreticulin Play Key Roles in the Development of Pemetrexed-Associated Resistance.
Chou HC; Chen JY; Lin DY; Wen YF; Lin CC; Lin SH; Lin CH; Chung TW; Liao EC; Chen YJ; Wei YS; Tsai YT; Chan HL
J Proteome Res; 2015 Nov; 14(11):4907-20. PubMed ID: 26452990
[TBL] [Abstract][Full Text] [Related]
3. CircPVT1 contributes to chemotherapy resistance of lung adenocarcinoma through miR-145-5p/ABCC1 axis.
Zheng F; Xu R
Biomed Pharmacother; 2020 Apr; 124():109828. PubMed ID: 31986409
[TBL] [Abstract][Full Text] [Related]
4. Circular RNA CDR1-AS contributes to pemetrexed and cisplatin chemoresistance through EGFR/PI3K signaling pathway in lung adenocarcinoma.
Mao Y; Xu R
Biomed Pharmacother; 2020 Mar; 123():109771. PubMed ID: 31881486
[TBL] [Abstract][Full Text] [Related]
5. Ku80 correlates with neoadjuvant chemotherapy resistance in human lung adenocarcinoma, but reduces cisplatin/pemetrexed-induced apoptosis in A549 cells.
Shang B; Jia Y; Chen G; Wang Z
Respir Res; 2017 Apr; 18(1):56. PubMed ID: 28399858
[TBL] [Abstract][Full Text] [Related]
6. The ERK-ZEB1 pathway mediates epithelial-mesenchymal transition in pemetrexed resistant lung cancer cells with suppression by vinca alkaloids.
Chiu LY; Hsin IL; Yang TY; Sung WW; Chi JY; Chang JT; Ko JL; Sheu GT
Oncogene; 2017 Jan; 36(2):242-253. PubMed ID: 27270426
[TBL] [Abstract][Full Text] [Related]
7. Gene and MicroRNA Perturbations of Cellular Response to Pemetrexed Implicate Biological Networks and Enable Imputation of Response in Lung Adenocarcinoma.
Gamazon ER; Trendowski MR; Wen Y; Wing C; Delaney SM; Huh W; Wong S; Cox NJ; Dolan ME
Sci Rep; 2018 Jan; 8(1):733. PubMed ID: 29335598
[TBL] [Abstract][Full Text] [Related]
8. Establishment of pemetrexed-resistant non-small cell lung cancer cell lines.
Zhang D; Ochi N; Takigawa N; Tanimoto Y; Chen Y; Ichihara E; Hotta K; Tabata M; Tanimoto M; Kiura K
Cancer Lett; 2011 Oct; 309(2):228-35. PubMed ID: 21742432
[TBL] [Abstract][Full Text] [Related]
9. Interplay of MKP-1 and Nrf2 drives tumor growth and drug resistance in non-small cell lung cancer.
Wang H; Liu K; Chi Z; Zhou X; Ren G; Zhou R; Li Y; Tang X; Wang XJ
Aging (Albany NY); 2019 Dec; 11(23):11329-11346. PubMed ID: 31811110
[TBL] [Abstract][Full Text] [Related]
10. Nitric oxide (NO) enhances pemetrexed cytotoxicity via NO‑cGMP signaling in lung adenocarcinoma cells in vitro and in vivo.
Nagai H; Yasuda H; Hatachi Y; Xue D; Sasaki T; Yamaya M; Sakamori Y; Togashi Y; Masago K; Ito I; Kim YH; Mio T; Mishima M
Int J Oncol; 2012 Jul; 41(1):24-30. PubMed ID: 22552400
[TBL] [Abstract][Full Text] [Related]
11. Prolonged pemetrexed pretreatment augments persistence of cisplatin-induced DNA damage and eliminates resistant lung cancer stem-like cells associated with EMT.
Tièche CC; Peng RW; Dorn P; Froment L; Schmid RA; Marti TM
BMC Cancer; 2016 Feb; 16():125. PubMed ID: 26895954
[TBL] [Abstract][Full Text] [Related]
12. Astaxanthin enhances pemetrexed-induced cytotoxicity by downregulation of thymidylate synthase expression in human lung cancer cells.
Liao KS; Wei CL; Chen JC; Zheng HY; Chen WC; Wu CH; Wang TJ; Peng YS; Chang PY; Lin YW
Regul Toxicol Pharmacol; 2016 Nov; 81():353-361. PubMed ID: 27693704
[TBL] [Abstract][Full Text] [Related]
13. High pemetrexed sensitivity of docetaxel-resistant A549 cells is mediated by TP53 status and downregulated thymidylate synthase.
Kuo WT; Tu DG; Chiu LY; Sheu GT; Wu MF
Oncol Rep; 2017 Nov; 38(5):2787-2795. PubMed ID: 28901493
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of both EGFR and ErbB3 improves the cellular response to pemetrexed in an established pemetrexed‑resistant lung adenocarcinoma A549 cell line.
Yu Z; Li XM; Liu SH; Liu B; Gao CH; Hou X
Oncol Rep; 2014 Apr; 31(4):1818-24. PubMed ID: 24549863
[TBL] [Abstract][Full Text] [Related]
15. Afatinib Overcomes Pemetrexed-Acquired Resistance in Non-Small Cell Lung Cancer Cells Harboring an EML4-ALK Rearrangement.
Kwon JH; Kim KJ; Sung JH; Suh KJ; Lee JY; Kim JW; Kim SH; Lee JO; Kim JW; Kim YJ; Lee KW; Kim JH; Bang SM; Kim S; Yoon SS; Lee JS
Cells; 2019 Nov; 8(12):. PubMed ID: 31795298
[TBL] [Abstract][Full Text] [Related]
16. Ginsenoside Rd reverses cisplatin resistance in non-small-cell lung cancer A549 cells by downregulating the nuclear factor erythroid 2-related factor 2 pathway.
Chian S; Zhao Y; Xu M; Yu X; Ke X; Gao R; Yin L
Anticancer Drugs; 2019 Sep; 30(8):838-845. PubMed ID: 31415285
[TBL] [Abstract][Full Text] [Related]
17. Expression profiling-based subtyping identifies novel non-small cell lung cancer subgroups and implicates putative resistance to pemetrexed therapy.
Hou J; Lambers M; den Hamer B; den Bakker MA; Hoogsteden HC; Grosveld F; Hegmans J; Aerts J; Philipsen S
J Thorac Oncol; 2012 Jan; 7(1):105-14. PubMed ID: 22134068
[TBL] [Abstract][Full Text] [Related]
18. Triptolide reverses the Taxol resistance of lung adenocarcinoma by inhibiting the NF-κB signaling pathway and the expression of NF-κB-regulated drug-resistant genes.
Jiang N; Dong XP; Zhang SL; You QY; Jiang XT; Zhao XG
Mol Med Rep; 2016 Jan; 13(1):153-9. PubMed ID: 26531258
[TBL] [Abstract][Full Text] [Related]
19. Elevated Expression of Nrf-2 and ABCG2 Involved in Multi-drug Resistance of Lung Cancer SP Cells.
Yang B; Ma YF; Liu Y
Drug Res (Stuttg); 2015 Oct; 65(10):526-31. PubMed ID: 25368906
[TBL] [Abstract][Full Text] [Related]
20. Genetic determinants of pemetrexed responsiveness and nonresponsiveness in non-small cell lung cancer cells.
Wu MF; Hsiao YM; Huang CF; Huang YH; Yang WJ; Chan HW; Chang JT; Ko JL
J Thorac Oncol; 2010 Aug; 5(8):1143-51. PubMed ID: 20559153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
